International Journal of Cancer Management

Published by: Kowsar

A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo

Zeinab Shirbaghaee 1 , 2 , Azam Bolhassani 1 , * , Abbas Mirshafiey 2 , Fatemeh Motevalli 1 and Negar Zohrei 1
Authors Information
1 Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, IR Iran
2 Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: December 28, 2015, 8 (6); e3991
  • Published Online: December 23, 2015
  • Article Type: Research Article
  • Received: September 16, 2015
  • Accepted: October 7, 2015
  • DOI: 10.17795/ijcp-3991

To Cite: Shirbaghaee Z, Bolhassani A, Mirshafiey A, Motevalli F, Zohrei N. A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo, Int J Cancer Manag. 2015 ; 8(6):e3991. doi: 10.17795/ijcp-3991.

Abstract
Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006; 24 Suppl 3-13[DOI][PubMed]
  • 2. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24(33-34): 5937-49[DOI][PubMed]
  • 3. Goncalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014; 18(6): 651-9[DOI][PubMed]
  • 4. Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin. 2009; 5(10): 671-89[PubMed]
  • 5. Thones N, Muller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology. 2007; 369(2): 375-88[DOI][PubMed]
  • 6. Kwak K, Yemelyanova A, Roden RB. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol. 2011; 23(2): 244-51[DOI][PubMed]
  • 7. Xu D, Wang D, Yang X, Cao M, Yu J, Wang Y. Fusion of HPV L1 into Shigella surface IcsA: a new approach in developing live attenuated Shigella-HPV vaccine. Antiviral Res. 2014; 102: 61-9[DOI][PubMed]
  • 8. Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, et al. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. Immunotherapy. 2012; 4(11): 1107-20[DOI][PubMed]
  • 9. Fraillery D, Baud D, Pang SY, Schiller J, Bobst M, Zosso N, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol. 2007; 14(10): 1285-95[DOI][PubMed]
  • 10. Echchannaoui H, Bianchi M, Baud D, Bobst M, Stehle JC, Nardelli-Haefliger D. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun. 2008; 76(5): 1940-51[DOI][PubMed]
  • 11. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, Guimaraes V, Rabot S, Alcocer-Gonzalez JM, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol. 2005; 175(11): 7297-302[PubMed]
  • 12. Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol. 2004; 78(23): 12901-9[DOI][PubMed]
  • 13. Xu W, Liu J, Gong W, Chen J, Zhu S, Zhang L. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1. Vaccine. 2011; 29(15): 2672-8[DOI][PubMed]
  • 14. Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, et al. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine. 2012; 30(22): 3286-94[DOI][PubMed]
  • 15. Basile G, Peticca M. Recombinant protein expression in Leishmania tarentolae. Mol Biotechnol. 2009; 43(3): 273-8[DOI][PubMed]
  • 16. Basak A, Shervani NJ, Mbikay M, Kolajova M. Recombinant proprotein convertase 4 (PC4) from Leishmania tarentolae expression system: purification, biochemical study and inhibitor design. Protein Expr Purif. 2008; 60(2): 117-26[DOI][PubMed]
  • 17. Breitling R, Klingner S, Callewaert N, Pietrucha R, Geyer A, Ehrlich G, et al. Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Expr Purif. 2002; 25(2): 209-18[PubMed]
  • 18. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun. 2005; 73(10): 6372-82[DOI][PubMed]
  • 19. Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J Gen Virol. 2007; 88: 217-25[DOI][PubMed]
  • 20. Mutiso JM, Macharia JC, Mutisya RM, Taracha E. Subcutaneous immunization against Leishmania major - infection in mice: efficacy of formalin-killed promastigotes combined with adjuvants. Rev Inst Med Trop Sao Paulo. 2010; 52(2): 95-100[PubMed]
  • 21. Hosseinzadeh S, Bolhassani A, Rafati S, Taheri T, Zahedifard F, Daemi A, et al. A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. Drug Deliv. 2013; 20(3-4): 190-8[DOI][PubMed]
  • 22. Zhang G, Huang X, Boldbaatar D, Battur B, Battsetseg B, Zhang H, et al. Construction of Neospora caninum stably expressing TgSAG1 and evaluation of its protective effects against Toxoplasma gondii infection in mice. Vaccine. 2010; 28(45): 7243-7[DOI][PubMed]
  • 23. Zou J, Huang XX, Yin GW, Ding Y, Liu XY, Wang H, et al. Evaluation of Toxoplasma gondii as a live vaccine vector in susceptible and resistant hosts. Parasit Vectors. 2011; 4: 168[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments